In Survey, Oncologists See Genomic Testing as Important Advance, But Value 'Below Expectations'

NEW YORK (GenomeWeb) – A survey of 132 oncologists has found that although around 70 percent of oncologists consider genomic testing to be an important advance in cancer, more than half also believe it is over-promoted because the technology’s value is “below expectations.”

Get the full story This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?

Be the first to comment

Leave a Reply

Your email address will not be published.